Name

Project Mine

Legal name

Project MinE

Website

https://projectmine.com

Company type

Private

Founded year

2013

Operating status

Operating

Ownership category

akta.pro rank

Product category

Genomic Research Consortium

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Other Computer Related Services (541519)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Public Health Genomics & Sequencing (WGS/Metagenomics) Networks (HLAJAIAK)

akta.pro secondary industry

Laboratory-Based Surveillance & Genomic Epidemiology (WGS/NGS) (HLAJABAC)

Keywords

• ALS genetics research
• Whole genome sequencing
• Genomic data consortium
• Rare disease genomics
• Neurodegenerative disease research

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Infrastructure, Personnel, Operations

Revenue model

1. Research Funding and Grants: Project MinE is a non-profit research consortium funded by the Dutch ALS Foundation and other research grants. All data used in publications was made accessible through funding by the Dutch ALS Foundation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Project MinE is an international research consortium of 30+ centers across 21 countries that collects, processes, and shares whole genome sequencing (WGS) data from ALS patients and healthy controls. It operates a controlled-access Data Access Program, a public Variant Browser, and downloadable GWAS summary statistics, supported by six specialized working groups covering phenotyping, association testing, epigenetics, structural variation, non-coding variation, and trans-ancestral genetics.

Product overview

Project MinE is the largest ALS genetics research consortium in the world, comprising over 30 research centers from 21 countries. The consortium operates as a unified research platform centered on a whole genome sequencing (WGS) database of ALS patients and healthy controls. The core offerings include the Project MinE Data Browser for variant visualization, downloadable GWAS summary statistics from landmark publications, a controlled WGS data access program for qualified researchers, and specialized working group services providing standardized methodologies for phenotyping, association testing, epigenetics, structural variation, non-coding variation, and trans-ancestral genetics research. The consortium has produced major publications in Nature Genetics (2016, 2021) and contributed harmonized data to the Longitude Prize on ALS initiative.

Differentiator

Problem solved

Functional benefit

Products and services

• Project MinE Data Browser Web-based variant browser enabling visualization and exploration of whole genomes from European-ancestry populations, ALS GWAS summary statistics, and burden test results across over 15,000 genes; aimed at qualified researchers studying ALS genetics.
• ALS GWAS Summary Statistics Downloadable GWAS summary statistics from cross-ancestry and European-ancestry meta-analyses, rare-variant burden analysis results, and eQTL SMR summary statistics for eQTLGen and MetaBrain datasets; intended for use by qualified ALS genetics researchers.
• WGS Data Access Program Controlled data access service that allows qualified researchers to request individual-level genotype or whole genome sequencing data via a formal application process, data access agreements, and secure data transfer mechanisms; available to both academic and commercial researchers, with commercial access limited.
• Working Group Research Services Six specialized working groups (Phenotyping, Analysis and Association Testing, Epigenetics, Genomic Structural Variation, Non-coding Genomic Variation, and Trans-Ancestral Genetics) providing standardized methodologies, SOPs, and collaborative research infrastructure for ALS genetics across the consortium.

Quantifiable outcome

• 25% of ALS patients now have identifiable genetic cause (up from 20%)
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and major.

• SURFsaracoreTechnology or IntegrationSURFsara computing platform in the Netherlands handles secure storage of Project MinE data. The system adheres to strict security protocols ensuring data protection and compliance with privacy regulations including GDPR. High-throughput computation continues to utilize SURF infrastructure.
• DNA Nexus (AWS)coreTechnology or IntegrationDNA Nexus platform on AWS chosen for processing Data Freeze 4 (DF4). The ISO27001-certified environment has all required legal and data-governance documents in place (DPIA, DPA, DMP, MSA, SCC). Platform enables joint access, scalable computational workflows, and integration of multimodal data including MRI, proteomics, and NfL biomarkers.
• Longitude Prize on ALSmajorStrategic or Co-development PartnerProject MinE is a key data contributor to the Longitude Prize on ALS, a £7.5 million global challenge. Project MinE harmonized previously scattered whole genome sequencing datasets into a single coherent dataset enabling 20 Discovery Award teams to pursue AI-driven ALS treatments. Winning teams gained access to genomic sequences of 9,000 patients plus epigenomics, transcriptomics, and proteomics data.
• Rostock University Medical CentercoreStrategic or Co-development PartnerNew consortium member added June 2026. Main ALS centre in Mecklenburg, Germany offering primary diagnostics, genetic testing, patient care for all stages of ALS. Expertise in deep phenotyping including cognitive/behavioral endophenotypes, molecular imaging, biomarker research, and patient-derived cell models. Prof. Dr. Andreas Hermann leads the Translational Neurodegeneration Section.
• Villa delle Ginestre HospitalcoreStrategic or Co-development PartnerNew consortium member added June 2026. Located in Palermo, Italy, this is one of Sicily's largest public rehabilitation hospitals. ALS Center provides comprehensive diagnostic, management, and rehabilitation services for ALS patients. Dr. Rossella Spataro leads the Rare Diseases Center and Prof. Francesca Luisa Conforti from University of Calabria contributes genetic expertise.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• deCODE genetics (Amgen): Population-scale human genetics company operating the world's largest WGS dataset for disease gene discovery — comparable technology platform and genomic data scale, but in a commercial and population-wide context.
• International Alliance of ALS/MND Associations: Umbrella organization coordinating national ALS/MND associations and the International Symposium on ALS/MND — directly comparable global convening and research-advocacy mission.
• NIH National ALS Registry / Biorepository: US federal ALS registry and biorepository linking patient data with biospecimens for research — comparable global-scale ALS patient cohort infrastructure, though with broader epidemiologic rather than WGS focus.
• Genomics England: Government-backed initiative sequencing genomes at population scale for clinical and research use — comparable large-cohort WGS infrastructure and controlled-access data model in a regulated environment.
• The ALS Association: Large US non-profit that funds ALS research and patient services globally, including genomics initiatives like the TREAT ALS network — comparable funder and ecosystem-builder role to Dutch ALS Foundation for Project MinE.

Direct peers

• Target ALS: Non-profit consortium funding collaborative ALS research, including genomic and transcriptomic resources and shared core facilities — overlapping mandate and operating model with Project MinE.
• ALS Therapy Development Institute (ALS TDI): Non-profit biotech focused on ALS drug discovery, maintaining its own large biobank and genomic resources of ALS patient samples — directly comparable disease-specific research mandate.
• Answer ALS: Large-scale multi-omic ALS research program generating WGS, RNA-seq, and iPSC-derived motor neuron data from ALS patients — directly comparable to Project MinE as the other flagship ALS genomics data resource.
• New York Genome Center (NYGC) ALS Consortium: NYGC's ALS Consortium performs large-scale WGS and multi-omic profiling of ALS patients using centralized sequencing infrastructure — comparable approach and population-scale ALS genomics focus.

Others

• UK Biobank: Large-scale population biobank with WGS and deep phenotyping available to approved researchers — comparable controlled-access, GDPR-style data governance model used for genetic discoveries across diseases including ALS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/_Makeityours
• Facebookfacebook.com/MineMakeityours

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Project Mine